CHRS compared with AMGN: revenue, margins and what each company keeps, and the suppliers and customers both name

CHRSCoherus Oncology, Inc.

Mkt capRevenueRevenue

AMGNAmgen Inc

Mkt capRevenueRevenue

Compare

CHRSCoherus Oncology, Inc.

AMGNAmgen Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only CHRS 7

GSKGlaxoSmithKlinesupplier

INOInovio Pharmaceuticalscustomer

—Junshi Biosciencesunlistedsupplier

—Janssen Research & Developmentunlistedsupplier

3 more · CHRS chain ›

Shared 0

No shared counterparties.

Only AMGN 12

PODDInsuletsupplier

CYTKCytokineticssupplier

ARWRArrowhead Pharmaceuticalssupplier

LGNDLigand Pharmaceuticalssupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

8 more · AMGN chain ›

CHRSCoherus Oncology, Inc.

0.77▲+2.39%· post 0.77

Mkt cap$119.0MRevenue$14MQ2 FY26Revenue$42MFY25

AMGNAmgen Inc

460.55▲+0.06%· post 460.42

ClosedNov 6 '26

Mkt cap$249.0BRevenue$10.4BQ3 FY26Revenue$36.8BFY25

Compare

ClosedNov 6 '26

CHRSCoherus Oncology, Inc.

AMGNAmgen Inc

0.77▲+2.39%post 0.77

Price

460.55▲+0.06%post 460.42

$119.0M

Mkt cap

$249.0B

Q2 FY26$14M

Revenue

$10.4BQ3 FY26

FY25$42M

Revenue

$36.8BFY25

CHRS0.77▲+2.39%vsAMGN460.55▲+0.06%ClosedNov 6 '26